Puma Biotechnology, Inc.

Release Summary

Puma Biotechnology has submitted a New Drug Application for PB272 (Neratinib) to the U.S. FDA for the extended adjuvant treatment of HER-2 positive early stage breast cancer.

Puma Biotechnology, Inc.